GlassScriptPhysician profile
Manzar J Shafi
NPI 1689655367
$5,234.91
in general payments reported to CMS, 2019-2025
45 companies · $737 in 2025
The $737 reported for 2025 was more than what 85% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
See the full distribution for Geriatric Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $737 · 2020: $510 · 2021: $647 · 2022: $1,131 · 2023: $783 · 2024: $690 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,209.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $673.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $591.03 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $496.89 | 2021-2025 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $422.72 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $333.45 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $283.99 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $258.98 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $231.69 | 2019-2024 | Veozah, Myrbetriq |
| Amgen INC. | $193.04 | 2019-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $124.15 | 2021-2024 | |
| Abbott Laboratories | $123.14 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.39 | 2020-2025 | Jardiance, Tradjenta |
| Exact Sciences Corporation | $100.63 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $94.01 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $88.64 | 2024-2025 | Voquezna |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manzar Shafi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.